You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
MediciNova Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
MediciNova Company Info
Acquire & dvlp high-qlty small molecule therapeuts
News & Analysis
These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.
The biotech announced a major new development partnership.
The small-cap pharmaceutical company announced a collaboration to develop a coronavirus vaccine.
Find out how these stocks survived a horrible day for the market.
The biopharma stopped a clinical trial early after a drug candidate showed impressive efficacy.
Lower-than-expected pricing for a secondary offering just took the shine off recently announced trial data.
These five stocks moved higher this past week.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.